Buschier
21/c Via Francia, Verona, Wisconsin, 53593, United States
Overview
Buschier AG based in Neumarkt (Italy) was founded in 2008. Our private equity orientated family-run business predominantly manages private capital and can therefore work independently from institutional investors and banks. Buschier AG can address the needs of small and medium-sized companies with investments ranging from €150,000 to €500,000 and conceivably higher investment sums for syndicates. Our private equity firm primarily supports enterprises based in the northern parts of Italy and in German-speaking countries. As an investor with an entrepreneurial approach to business, Buschier AG is a trusted partner who actively participates in development and provides strategic guidance. To live up to this approach, the firm also is actively involved in controlling and supervising the investee company to take it to the next level.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Financial Services
Investment portfolio
- Innovacell
Participated · Equity · Apr 2012
Innovacell is a Bregenz, Austria-based biotechnology company developing a cell-therapy called ICES13. ICES13 is being developed for the treatment of stress-urinary incontinence and faecal incontinence. The company has raised €8.3m (approximately $11m), provided in two tranches, to fund the clinical development of ICES13. Management plans to use the proceeds to complete a Phase III study. CEO Dr. Ekkehart Steinhuber expected first Phase III results in the fourth quarter of 2012 and central EU authorisation from the European Medicines Agency in 2013. Innovacell employs 20 staff and engages numerous outside experts.
Team
No current team members are available.